CVRx logo

CVRxNASDAQ: CVRX

Profile

Sector:

Healthcare

Country:

United States

IPO:

30 June 2021

Next earnings report:

24 January 2025

Last dividends:

N/A

Next dividends:

N/A
$328.05 M
-52%vs. 3y high
60%vs. sector
-vs. 3y high
-vs. sector
-40%vs. 3y high
82%vs. sector
-71%vs. 3y high
69%vs. sector

Price

after hours | 54 min ago
$13.52-$0.08(-0.59%)

Dividend

No data over the past 3 years
$13.37 M$15.20 M
$13.37 M-$13.10 M

Analysts recommendations

Institutional Ownership

CVRX Latest News

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
globenewswire.com20 November 2024 Sentiment: -

MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast.

CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript
seekingalpha.com29 October 2024 Sentiment: NEUTRAL

CVRx, Inc. (NASDAQ:CVRX ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call.

CVRx announces new CPT® Category I codes for Barostim
globenewswire.com18 October 2024 Sentiment: POSITIVE

MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (“Barostim”) to treat the symptoms of heart failure.

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
globenewswire.com15 October 2024 Sentiment: POSITIVE

MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
zacks.com16 September 2024 Sentiment: POSITIVE

CVRx announces the publication of positive study data for its Barostim therapy.

CVRx Announces Appointment of Two New Board Members
globenewswire.com03 September 2024 Sentiment: POSITIVE

Kevin Ballinger and Mitch Hill appointed as new independent Board members Kevin Ballinger and Mitch Hill appointed as new independent Board members

CVRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Shareholders to Contact the Firm Today!
accesswire.com20 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
globenewswire.com19 August 2024 Sentiment: NEGATIVE

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX
accesswire.com19 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

CVRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Investors to Contact the Firm Today!
accesswire.com18 August 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.

What type of business is CVRx?

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

What sector is CVRx in?

CVRx is in the Healthcare sector

What industry is CVRx in?

CVRx is in the Medical Devices industry

What country is CVRx from?

CVRx is headquartered in United States

When did CVRx go public?

CVRx initial public offering (IPO) was on 30 June 2021

What is CVRx website?

https://www.cvrx.com

Is CVRx in the S&P 500?

No, CVRx is not included in the S&P 500 index

Is CVRx in the NASDAQ 100?

No, CVRx is not included in the NASDAQ 100 index

Is CVRx in the Dow Jones?

No, CVRx is not included in the Dow Jones index

When was CVRx the previous earnings report?

No data

When does CVRx earnings report?

The next expected earnings date for CVRx is 24 January 2025